Search

 

 

 

 

Image of BioMarin building

Our history

Our journey of fighting rare diseases started in 1997, at a time when the treatment of rare disease was still rare. With a relentless commitment to helping patients battle rare genetic diseases, BioMarin is resolved to overcome the biggest scientific challenges and has made numerous breakthroughs in developing innovative therapies for rare disease patients to achieve the optimal outcomes.

Read more about our history on BioMarin.com

BioMarin logo

At a glance

BioMarin Pharmaceutical Australia Pty Ltd

Location: 119 Willoughby Rd, Crows Nest, NSW 2065
Phone: 02 9967 8662
Email: anz@bmrn.com
Founded: 2012

Managing Director: Adrian Goodall
Focus: Rare genetic diseases

Products included in Australian Register of Therapeutic Goods (ARTG):

  • BRINEURA® (cerliponase alfa) for the treatment of neuronal ceroid lipofuscinosis type 2 (CLN2) disease, also known as tripeptidyl peptidase 1 (TPP1) deficiency.
  • KUVAN® (sapropterin dihydrochloride) Tablets for Oral Use and Powder for Oral Solution for the treatment of hyperphenylalaninemia (HPA) by reducing blood phenylalanine levels in patients with phenylketonuria (PKU) or tetrahydrobiopterin (BH4) deficiency.
  • PALYNZIQ® (pegvaliase) for the treatment of patients with phenylketonuria (PKU) whose blood phenylalanine levels cannot be adequately controlled by other means such as by diet.
  • NAGLAZYME® (galsulfase (rch)) for the treatment of Mucopolysaccharidosis VI (MPS VI) storage disorder, a disease in which the enzyme level of Nacetylgalactosamine 4-sulfatase is absent or lower than normal.
  • VIMIZIM® (elosulfase alfa (rch) for the treatment of MPS IVA (Mucopolysaccharidosis Type IVA, Morquio A Syndrome).
  • VOXZOGO® (vosoritide) for the treatment of achondroplasia in paediatric patients whose epiphyses are not closed.

Parent company: BioMarin Pharmaceutical Inc